| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 7 | 2019 | 741 | 1.350 |
Why?
|
| Pharmacogenetics | 7 | 2019 | 443 | 1.020 |
Why?
|
| Antihypertensive Agents | 4 | 2018 | 249 | 0.920 |
Why?
|
| Cardiovascular Agents | 4 | 2015 | 54 | 0.900 |
Why?
|
| Dyslipidemias | 3 | 2018 | 106 | 0.840 |
Why?
|
| Atrial Fibrillation | 4 | 2014 | 350 | 0.730 |
Why?
|
| Heart Failure | 6 | 2019 | 1180 | 0.710 |
Why?
|
| Cardiovascular Diseases | 7 | 2015 | 705 | 0.690 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 70 | 0.660 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 96 | 0.650 |
Why?
|
| Cardiology | 3 | 2015 | 115 | 0.640 |
Why?
|
| Students, Medical | 1 | 2023 | 418 | 0.600 |
Why?
|
| Coronary Disease | 5 | 2000 | 260 | 0.540 |
Why?
|
| Physicians | 1 | 2023 | 689 | 0.510 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2005 | 105 | 0.440 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 1043 | 0.410 |
Why?
|
| Hemorrhage | 1 | 2014 | 278 | 0.400 |
Why?
|
| Anticoagulants | 1 | 2014 | 426 | 0.360 |
Why?
|
| Lipids | 1 | 2012 | 271 | 0.360 |
Why?
|
| Proteinuria | 1 | 2010 | 67 | 0.350 |
Why?
|
| Myocardial Ischemia | 3 | 2005 | 161 | 0.330 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2010 | 219 | 0.290 |
Why?
|
| Humans | 43 | 2023 | 89063 | 0.280 |
Why?
|
| Drug Prescriptions | 2 | 2019 | 144 | 0.280 |
Why?
|
| Physician-Patient Relations | 3 | 2023 | 625 | 0.270 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 280 | 0.260 |
Why?
|
| Disease Outbreaks | 1 | 2005 | 154 | 0.240 |
Why?
|
| Metabolic Syndrome | 1 | 2005 | 121 | 0.240 |
Why?
|
| Primary Prevention | 2 | 2000 | 81 | 0.220 |
Why?
|
| Faculty | 1 | 2023 | 33 | 0.220 |
Why?
|
| Electric Countershock | 1 | 2003 | 53 | 0.220 |
Why?
|
| Point-of-Care Systems | 3 | 2019 | 148 | 0.220 |
Why?
|
| Pharmacogenomic Testing | 3 | 2019 | 98 | 0.210 |
Why?
|
| Cardiac Imaging Techniques | 2 | 2012 | 25 | 0.210 |
Why?
|
| Cardiac Catheterization | 3 | 2012 | 302 | 0.200 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 1993 | 67 | 0.200 |
Why?
|
| Communication | 2 | 2023 | 457 | 0.200 |
Why?
|
| Thoracic Surgery | 2 | 2012 | 44 | 0.200 |
Why?
|
| Societies, Medical | 2 | 2018 | 570 | 0.190 |
Why?
|
| United States | 9 | 2018 | 6955 | 0.190 |
Why?
|
| Stroke Volume | 2 | 2019 | 462 | 0.180 |
Why?
|
| Hypertriglyceridemia | 1 | 2000 | 68 | 0.180 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 43 | 0.170 |
Why?
|
| Hypercholesterolemia | 1 | 2000 | 159 | 0.170 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 105 | 0.170 |
Why?
|
| Risk Factors | 6 | 2012 | 5466 | 0.170 |
Why?
|
| Physician's Role | 2 | 2017 | 177 | 0.170 |
Why?
|
| Hemangioma, Cavernous | 1 | 2019 | 69 | 0.170 |
Why?
|
| Precision Medicine | 3 | 2019 | 410 | 0.160 |
Why?
|
| Diltiazem | 1 | 1998 | 7 | 0.160 |
Why?
|
| Drug Labeling | 2 | 2017 | 41 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2019 | 36 | 0.160 |
Why?
|
| Risk | 2 | 2018 | 657 | 0.160 |
Why?
|
| Sterols | 1 | 2018 | 16 | 0.160 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2018 | 28 | 0.160 |
Why?
|
| Dyspnea | 3 | 1996 | 75 | 0.150 |
Why?
|
| Intestinal Absorption | 1 | 2018 | 124 | 0.150 |
Why?
|
| Blood Pressure Determination | 1 | 2018 | 60 | 0.150 |
Why?
|
| Tachycardia, Ventricular | 1 | 1998 | 124 | 0.150 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 25 | 0.150 |
Why?
|
| Anticholesteremic Agents | 1 | 2018 | 137 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2000 | 351 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 1176 | 0.140 |
Why?
|
| Echocardiography | 5 | 2012 | 937 | 0.140 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2019 | 229 | 0.140 |
Why?
|
| Cerebral Hemorrhage | 1 | 2019 | 338 | 0.140 |
Why?
|
| Aged | 13 | 2018 | 19077 | 0.140 |
Why?
|
| Dobutamine | 1 | 1996 | 61 | 0.130 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 1996 | 21 | 0.130 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1996 | 72 | 0.130 |
Why?
|
| Female | 18 | 2019 | 46011 | 0.130 |
Why?
|
| Hypotension | 1 | 1996 | 71 | 0.130 |
Why?
|
| Male | 16 | 2019 | 42251 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 604 | 0.130 |
Why?
|
| Evidence-Based Medicine | 4 | 2005 | 433 | 0.130 |
Why?
|
| Clinical Medicine | 1 | 2015 | 34 | 0.130 |
Why?
|
| Life Style | 3 | 2000 | 172 | 0.130 |
Why?
|
| Exercise Test | 1 | 1996 | 165 | 0.130 |
Why?
|
| Intestines | 1 | 2018 | 416 | 0.120 |
Why?
|
| Echocardiography, Doppler | 1 | 1996 | 186 | 0.120 |
Why?
|
| Disease Progression | 1 | 2019 | 1488 | 0.120 |
Why?
|
| Posture | 2 | 1993 | 124 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 599 | 0.120 |
Why?
|
| Treatment Outcome | 6 | 2019 | 8203 | 0.120 |
Why?
|
| Genome, Human | 1 | 2019 | 767 | 0.120 |
Why?
|
| Program Development | 1 | 2014 | 123 | 0.110 |
Why?
|
| Mitral Valve Prolapse | 1 | 1993 | 24 | 0.110 |
Why?
|
| Severity of Illness Index | 4 | 2001 | 1837 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2014 | 187 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 967 | 0.100 |
Why?
|
| Blood Proteins | 1 | 1992 | 145 | 0.100 |
Why?
|
| Counterpulsation | 1 | 1992 | 21 | 0.100 |
Why?
|
| Lipoproteins | 1 | 1992 | 136 | 0.100 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1992 | 21 | 0.100 |
Why?
|
| Patient Selection | 3 | 2015 | 682 | 0.100 |
Why?
|
| Ventricular Function, Left | 1 | 1996 | 603 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 385 | 0.100 |
Why?
|
| Middle Aged | 13 | 2019 | 25863 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2014 | 2290 | 0.090 |
Why?
|
| Insulin Resistance | 2 | 2005 | 353 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2010 | 899 | 0.090 |
Why?
|
| General Practitioners | 1 | 2010 | 11 | 0.090 |
Why?
|
| Biomarkers | 2 | 2018 | 1755 | 0.090 |
Why?
|
| Diabetes Complications | 2 | 2000 | 170 | 0.080 |
Why?
|
| Thrombosis | 1 | 1992 | 302 | 0.080 |
Why?
|
| Diuretics | 2 | 1999 | 75 | 0.080 |
Why?
|
| Adult | 7 | 2018 | 26507 | 0.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 1999 | 91 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 362 | 0.070 |
Why?
|
| Cardiomegaly | 1 | 1988 | 120 | 0.070 |
Why?
|
| Models, Biological | 1 | 2014 | 1763 | 0.070 |
Why?
|
| Oxygen | 1 | 1991 | 742 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 531 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 2 | 1999 | 143 | 0.060 |
Why?
|
| Algorithms | 1 | 2014 | 1875 | 0.060 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 61 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 92 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2019 | 4273 | 0.060 |
Why?
|
| Stroke | 1 | 2014 | 982 | 0.060 |
Why?
|
| Heart-Assist Devices | 1 | 1992 | 756 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 1 | 2005 | 149 | 0.060 |
Why?
|
| Obesity | 2 | 2000 | 966 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2005 | 396 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 1999 | 373 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 3657 | 0.050 |
Why?
|
| Diet | 1 | 2005 | 442 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 376 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2005 | 1533 | 0.050 |
Why?
|
| Coronary Circulation | 2 | 1992 | 131 | 0.050 |
Why?
|
| Contraindications | 1 | 2001 | 70 | 0.050 |
Why?
|
| Microvascular Angina | 1 | 2000 | 1 | 0.050 |
Why?
|
| Coronary Angiography | 2 | 2012 | 242 | 0.050 |
Why?
|
| Prognosis | 2 | 2001 | 3773 | 0.050 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2012 | 161 | 0.050 |
Why?
|
| Niacin | 1 | 2000 | 37 | 0.050 |
Why?
|
| Morbidity | 1 | 2001 | 149 | 0.050 |
Why?
|
| Guideline Adherence | 2 | 2012 | 229 | 0.050 |
Why?
|
| Physical Examination | 1 | 2001 | 148 | 0.050 |
Why?
|
| Family Practice | 1 | 2000 | 82 | 0.040 |
Why?
|
| Triglycerides | 1 | 2000 | 232 | 0.040 |
Why?
|
| Hypolipidemic Agents | 1 | 2000 | 99 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2019 | 1714 | 0.040 |
Why?
|
| Genotype | 2 | 2015 | 1848 | 0.040 |
Why?
|
| Cause of Death | 1 | 2000 | 266 | 0.040 |
Why?
|
| Administration, Oral | 2 | 1998 | 682 | 0.040 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2019 | 85 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 13 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 6777 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 783 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 1999 | 121 | 0.040 |
Why?
|
| Cholesterol | 1 | 2000 | 357 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2001 | 298 | 0.040 |
Why?
|
| Chicago | 2 | 2014 | 1423 | 0.040 |
Why?
|
| Proprotein Convertase 9 | 1 | 2018 | 20 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 1999 | 98 | 0.040 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2001 | 329 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 434 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 160 | 0.040 |
Why?
|
| Research | 1 | 2019 | 252 | 0.040 |
Why?
|
| Exercise | 1 | 2000 | 322 | 0.040 |
Why?
|
| Digoxin | 1 | 1997 | 21 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 1715 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 212 | 0.030 |
Why?
|
| Smoking | 1 | 2000 | 620 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 329 | 0.030 |
Why?
|
| Recurrence | 1 | 1999 | 1140 | 0.030 |
Why?
|
| Social Perception | 1 | 2017 | 95 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 1997 | 89 | 0.030 |
Why?
|
| Angina Pectoris | 1 | 1996 | 28 | 0.030 |
Why?
|
| Time Factors | 2 | 2005 | 5320 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1997 | 232 | 0.030 |
Why?
|
| Cardiac Output | 1 | 1996 | 156 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2017 | 222 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 1996 | 198 | 0.030 |
Why?
|
| Sympatholytics | 1 | 1994 | 5 | 0.030 |
Why?
|
| Hospitalization | 1 | 2001 | 876 | 0.030 |
Why?
|
| Clonidine | 1 | 1994 | 33 | 0.030 |
Why?
|
| Anesthesia, Local | 1 | 1994 | 27 | 0.030 |
Why?
|
| Bupivacaine | 1 | 1994 | 45 | 0.030 |
Why?
|
| Incidence | 1 | 1999 | 1592 | 0.030 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1994 | 52 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2018 | 9003 | 0.030 |
Why?
|
| Analgesia | 1 | 1994 | 58 | 0.030 |
Why?
|
| Heart Auscultation | 1 | 1993 | 2 | 0.030 |
Why?
|
| Endocarditis, Bacterial | 1 | 1993 | 38 | 0.030 |
Why?
|
| Anesthesia | 1 | 1994 | 169 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 1994 | 251 | 0.030 |
Why?
|
| Hospitals, University | 1 | 1992 | 195 | 0.030 |
Why?
|
| American Heart Association | 1 | 2012 | 94 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2012 | 88 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 2657 | 0.020 |
Why?
|
| Angiography | 1 | 2012 | 208 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1993 | 197 | 0.020 |
Why?
|
| Equipment Failure | 1 | 1992 | 121 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 824 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1991 | 113 | 0.020 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1993 | 192 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2612 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 1996 | 779 | 0.020 |
Why?
|
| Ventricular Function, Right | 1 | 1991 | 146 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2863 | 0.020 |
Why?
|
| Systole | 1 | 2010 | 115 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 168 | 0.020 |
Why?
|
| Awareness | 1 | 2010 | 89 | 0.020 |
Why?
|
| Prevalence | 1 | 1993 | 1240 | 0.020 |
Why?
|
| Comorbidity | 1 | 1992 | 948 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1992 | 729 | 0.020 |
Why?
|
| Age Factors | 1 | 1992 | 1867 | 0.020 |
Why?
|
| Hypoxia | 1 | 1993 | 650 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3443 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 359 | 0.020 |
Why?
|
| Intermittent Claudication | 1 | 2005 | 20 | 0.020 |
Why?
|
| Nutrition Policy | 1 | 2005 | 13 | 0.020 |
Why?
|
| Aneurysm | 1 | 2005 | 60 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 6288 | 0.020 |
Why?
|
| Premedication | 2 | 1994 | 58 | 0.020 |
Why?
|
| Extremities | 1 | 2005 | 169 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 988 | 0.010 |
Why?
|
| Length of Stay | 1 | 2005 | 732 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 1212 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2001 | 38 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 1889 | 0.010 |
Why?
|
| Ventricular Dysfunction | 1 | 2001 | 28 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 833 | 0.010 |
Why?
|
| Heart Valve Diseases | 1 | 2001 | 115 | 0.010 |
Why?
|
| Enflurane | 1 | 1994 | 2 | 0.010 |
Why?
|
| Sufentanil | 1 | 1994 | 3 | 0.010 |
Why?
|
| Receptors, Adrenergic | 1 | 1994 | 15 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2005 | 2275 | 0.010 |
Why?
|
| Diazepam | 1 | 1994 | 27 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 1994 | 60 | 0.010 |
Why?
|
| Epinephrine | 1 | 1994 | 86 | 0.010 |
Why?
|
| Placebos | 1 | 1994 | 214 | 0.010 |
Why?
|
| Urodynamics | 1 | 1994 | 122 | 0.010 |
Why?
|
| Nitrous Oxide | 1 | 1994 | 107 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1994 | 229 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1994 | 894 | 0.010 |
Why?
|
| Respiration | 1 | 1994 | 267 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1994 | 302 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1994 | 242 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1994 | 205 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1994 | 493 | 0.010 |
Why?
|
| Heart Rate | 1 | 1994 | 493 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1994 | 836 | 0.010 |
Why?
|